Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories

Ziel

Despite recent advances, we still lack a coherent framework explaining how genetic lesions, aberrant cell fate decisions and host factors intersect to drive immunological neoplasms (lymphoma). We have uncovered an entirely new dimension: gender bias as a fundamental driver of lymphoma evolution. Our data show that a newly discovered type of lymphoma called BN2-DLBCL, defined by SPEN and NOTCH2 truncations, is specifically highly aggressive in women and rooted in the biology of aged/autoimmune B cells (AiBCs); cells classically linked to autoimmunity. This suggests a central role for female gender effects where immune dysfunction, chronic inflammation, and failed X-chromosome inactivation (XCI) converge. We hypothesize that SPEN loss destabilizes XCI, unleashing bi-allelic expression of X-encoded TLR7/IRAK1 and hyperactive inflammatory signaling; NOTCH2 mutations reroute these signals into AiBC fate, creating lymphoma precursors that expand clonally, exhaust T cells, and reshape immune microenvironments. The result is a uniquely female-biased malignant trajectory, overturning conventional lymphoma paradigms. With X-SeLECT (X-chromosome role in SEx-dependent Lymphoma Evolution and Clonal Trajectories) we will systematically dissect this biology. Using single-cell multi-omics, spatial proteogenomics, real-time dynamics (3-photon microscopy), and lineage tracing, we will reconstruct the stepwise clonal evolution of AiBCs into BN2-DLBCL and define the gender-specific immune circuits that sustain them. Finally, we will exploit these insights to uncover sex-specific vulnerabilities, testing how TLR/IRAK blockade, statins, and immune checkpoint synergy can dismantle these malignant networks. This project will deliver a paradigm shift: establishing AiBCs as the first bona fide lymphoma-initiating and repopulating cells, demonstrating that gender and X-linked immunity are central to cancer biology, and charting the way toward precision, sex-informed therapies in lymphoma.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC - HORIZON ERC Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2025-ADG

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Netto-EU-Beitrag
€ 3 499 123,75
Adresse
CARRETERA DE CAN RUTI CAMI DE LES ESCOLES S/N
08916 Badalona
Spanien
Region
Este Cataluña Barcelona
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (1)